The minimal clinically important difference of the control of allergic rhinitis and asthma test (CARAT): Cross-cultural validation and relation with pollen counts by Van Der Leeuw, S. (Sander) et al.
ARTICLE OPEN
The minimal clinically important difference of the control of
allergic rhinitis and asthma test (CARAT): cross-cultural
validation and relation with pollen counts
Sander van der Leeuw1,2, Thys van der Molen1,2, PN Richard Dekhuijzen3, Joao A Fonseca4, Frederik A van Gemert1,2,
Roy Gerth van Wijk5, Janwillem WH Kocks1,2, Helma Oosterom1,2, Roland A Riemersma1,2, Ioanna G Tsiligianni1,2, Letty A de Weger6,
Joanne NG Oude Elberink2,7 and Bertine MJ Flokstra-de Blok1,2
BACKGROUND: The Control of Allergic Rhinitis and Asthma Test (CARAT) monitors control of asthma and allergic rhinitis.
AIMS: To determine the CARAT’s minimal clinically important difference (MCID) and to evaluate the psychometric properties of the
Dutch CARAT.
METHODS: CARAT was applied in three measurements at 1-month intervals. Patients diagnosed with asthma and/or rhinitis were
approached. MCID was evaluated using Global Rating of Change (GRC) and standard error of measurement (s.e.m.). Cronbach’s
alpha was used to evaluate internal consistency. Spearman’s correlation coefﬁcients were calculated between CARAT, the Asthma
Control Questionnaire (ACQ5) and the Visual Analog Scale (VAS) on airway symptoms to determine construct and longitudinal
validity. Test–retest reliability was evaluated with intra-class correlation coefﬁcient (ICC). Changes in pollen counts were compared
with delta CARAT and ACQ5 scores.
RESULTS: A total of 92 patients were included. The MCID of the CARAT was 3.50 based on GRC scores; the s.e.m. was 2.83.
Cronbach’s alpha was 0.82. Correlation coefﬁcients between CARAT and ACQ5 and VAS questions ranged from 0.64 to 0.76
(Po0.01). Longitudinally, correlation coefﬁcients between delta CARAT scores and delta ACQ5 and VAS scores ranged from 0.41 to
0.67 (Po0.01). Test–retest reliability showed an ICC of 0.81 (Po0.01) and 0.80 (Po0.01). Correlations with pollen counts were
higher for CARAT than for ACQ5.
CONCLUSIONS: This is the ﬁrst investigation of the MCID of the CARAT. The CARAT uses a whole-point scale, which suggests that
the MCID is 4 points. The CARAT is a valid and reliable tool that is also applicable in the Dutch population.
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INTRODUCTION
Asthma and allergic rhinitis are common diseases that have a
negative inﬂuence on social life, school performance and work
productivity.1 Epidemiologic studies have shown that asthma and
allergic rhinitis frequently co-exist; i.e., 70–90% of patients with
asthma also have allergic rhinitis and 40–50% of patients with
allergic rhinitis also have asthma.2,3 Furthermore, there is a
probable association between the severity of asthma and allergic
rhinitis.2–5
Most patients with asthma and/or allergic rhinitis are treated by
general practitioners. Given the variation in patients, symptoms
and clinical presentation, general practitioners face uncertainty
regarding asthma and allergic rhinitis management.6,7 Although
the majority of asthma patients also suffer from allergic rhinitis,
generally used questionnaires for asthma disease control do not
take into account the impact of allergic rhinitis.8–11 In addition,
general practitioners are often not aware of allergic rhinitis
symptoms in their asthma patients, although the allergic rhinitis
symptoms might have a large impact on their asthma control.12
This results in a large number of patients who do not receive
appropriate care despite the availability of effective treatment
options.11
The ARIA guidelines recommend optimal control of both
asthma and allergic rhinitis airway disease as the primary goal
of their treatment.1,13 A combined approach of upper and lower
airway disease management is a key issue that has been
extensively proposed.1,13–15 To assess the effects of treatment
on the control, validated questionnaires have been identiﬁed as
key instruments.16–18
The Control of Allergic Rhinitis and Asthma Test (CARAT)
questionnaire was created and validated to measure disease
control of both asthma and allergic rhinitis.19,20 However, the
minimal clinically important difference (MCID), a vital measure for
the interpretation of CARAT scores,21 is unknown. Moreover, the
psychometric properties of the CARAT have not yet been tested
outside the country of development. The objective of this study
was to establish the MCID of the CARAT. Additional objectives
were to evaluate the internal consistency, cross-sectional validity,
longitudinal validity and test–retest reliability for the Dutch CARAT
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version. Furthermore, the sensitivity of the CARAT in relation to
the inﬂuence of pollen counts was investigated.
MATERIALS AND METHODS
Study design and procedure
The longitudinal study consisted of three measurements (T1, T2 and T3)
with 1-month intervals during the period May through August 2012. At
each time point, the questionnaire packages included CARAT, an asthma
control questionnaire (ACQ5), three visual analog scales (VAS) on
pulmonary symptoms, and a question concerning medication use during
the preceding month. The questionnaire packages at T2 and T3 also
included a global rating of change (GRC) question. The questionnaires
were distributed to the patients by mail with an accompanying letter from
both their clinician and the researcher, explaining the objectives of the
study, along with an informed consent form. Participants were requested
to return the completed questionnaires and informed consent form in a
prepaid envelope. Reminders were sent once, in case a participant had not
returned the questionnaire within 1 week after the aimed date.
Participants
Patients were recruited from the outpatient clinics of the departments of
allergy or pulmonary diseases of the university hospitals in Groningen,
Rotterdam and Nijmegen. In addition, patients were recruited from primary
care practices in Groningen, Appingedam and Harlingen. Patients aged
18–70 years with a physician diagnosis of asthma and/or allergic rhinitis
were asked to participate. Patients with insufﬁcient command of the Dutch
language and those diagnosed with dementia were excluded from the
study. At each centre, baseline characteristics of the patients were
obtained from patient ﬁles. These characteristics included age, sex,
diagnosis, age of onset, respiratory co-morbidity, type of allergen and,
where available, skin prick test, speciﬁc IgE and/or lung function. Informed
consent was obtained from all patients. The local Medical Ethical Review
Commission deemed that permission from the commission was not
required (METc 2012.096).
Outcome measures
CARAT. The CARAT consists of 10 questions scored on a 4-point Likert
scale with a recall period of 4 weeks.20 Seven questions relate to the
frequency of airway symptoms, four of which focus on upper airway
symptoms and three focus on lower airway symptoms. The other three
questions deal with sleep impairment, activity limitations and the need for
higher doses of medication. The total score is calculated by summing up
the scores of all 10 questions, resulting in a range of 0–30 points, with a
higher score representing better control. The CARAT consists of two
domains: allergic rhinitis (question no. 1–4) and asthma (question no.
5–10).20 The CARAT was originally developed and validated in Portugal and
translated into Dutch following international recommendations. These
comprise repetitive rounds of forward translation, backward translation,
comparison of back translation with original until consensus is obtained by
the expert panel and testing in patients in terms of comprehension.22
ACQ5. The asthma control questionnaire (ACQ5) consists of ﬁve
questions that are scored on a 7-point Likert scale with a recall period of
1 week. The total ACQ5 score is the mean score of all questions (ranging
from 0 to 6), a lower score representing better control. The ACQ5 has been
shown to be reliable (intra-class correlation coefﬁcient (ICC) = 0.90,
Po0.0001) and has strong evaluative properties for the measurement of
asthma control.16 It has also been shown to have good discriminative
properties to distinguish patients who have well-controlled asthma (score
⩽ 0.75 points) from those with uncontrolled asthma (score ⩾ 1.5 points).23
VAS. Three visual analog scales were used to assess all airway symptoms
(VAS-all), lower airway symptoms (VAS-low) and upper airway symptoms
(VAS-up). Participants were asked to mark the position on a 10-centimetre
line corresponding to the amount of symptoms they experienced in the
preceding week.24
GRC. At T2 and T3, a global rating of change (GRC) question with a
15-point scale was used to monitor the participants’ subjective experience
of change in symptoms of asthma and allergic rhinitis, compared with the
previous measurement. The score range of this question was from − 7
(extremely worse) through 0 (no change) to 7 (extremely better). The GRC
question was used for the determination of the MCID of the CARAT.25
Pollen counts. During the study, daily pollen-speciﬁc counts were
provided by the Leiden University Medical Center. Grass and birch pollen
counts were used for the analysis because they are the major cause of
pollen-induced symptoms in Northern Europe.26
Statistical analyses
Statistical analyses were performed using SPSS 19.
The MCID of the CARAT was established using both an anchor-based
and a distribution-based method. For the anchor-based method, the GRC
scores at T2 were used. This GRC measurement represents the difference in
symptoms between T1 and T2. Patients were divided into four categories
on the basis of GRC scores: no difference (−1, 0, 1), minimal difference
(−3,− 2, 2, 3), moderate difference (−5, − 4, 4, 5) and large difference (−7,
− 6, 6, 7). For each category, the mean difference in CARAT score between
T1 and T2 was calculated. The outcome of the GRC category minimal
difference was considered as the MCID.25 For the distribution-based
method, the standard error of measurement (s.e.m.) was calculated using
the CARAT scores at T1 and used as a threshold to further establish
the MCID.
The internal consistency of the CARAT was evaluated by calculating
Cronbach’s alpha. A Cronbach’s alpha of at least 0.70 is required for the
comparison of groups of patients.27
The cross-sectional construct validity of the CARAT was evaluated by
calculating Spearman’s correlation coefﬁcients for CARAT (total and
domains scores) with ACQ5 and VAS scores (VAS-all, VAS-up and VAS-
low). A priori expectations were based on the Portuguese version of the
CARAT, which showed correlation coefﬁcients ranging from 0.6 to 0.8 with
the ACQ5 and VAS scores.20 The CARAT domain allergic rhinitis was
expected to correlate best with VAS-up and the CARAT domain asthma
was expected to correlate best with VAS-low.
The longitudinal validity of the CARAT was evaluated by calculating
Spearman’s correlation coefﬁcients for delta scores of the CARAT (total and
domains scores) with delta scores of the ACQ5 and VAS scores. Delta
scores were calculated as T2 minus T1 and T3 minus T2. A priori
expectations were based on the Portuguese version of the CARAT, which
showed longitudinal correlation coefﬁcients ranging from 0.4 to 0.6 with
the ACQ5 and VAS scores.21
The test–retest reliability of the CARAT was evaluated by calculating ICC
of CARAT scores for the ﬁrst interval (T1, T2) and second (T2, T3) interval.
Only patients in the ‘no difference’ category based on the GRC scores
measured at T2 and T3 were included in these analyses.
The discriminative properties of the CARAT were investigated by
dividing the patients into two groups on the basis of ACQ5 scores at T1:
(1) patients with ACQ5 score o1.5 (well and partly controlled) and
(2) patients with ACQ5 score ⩾ 1.5 (uncontrolled).23 The mean CARAT score
for both the groups was compared using an independent samples t-test.
The a priori expectation was to ﬁnd a signiﬁcantly lower mean CARAT score
for group 2 compared with group 1.
To investigate the sensitivity of the CARAT to the inﬂuence of pollen
counts, patients with a history of clinical reactivity to pollen (grass and/or
birch) were selected. Depending on the date of completing the
questionnaire package, a mean pollen count over the previous 4 weeks
was calculated for each patient at each measurement point (T1, T2 and T3).
Pearson’s correlation coefﬁcients were calculated between delta pollen
counts and delta CARAT scores, as well as delta ACQ5 scores. A higher
correlation with pollen counts was expected for CARAT scores than for
ACQ5 scores.
RESULTS
Of the 176 approached patients, 92 patients completed T1
(response rate 53%). Response rates of T2 (89%) and T3 (88%)
were much higher. An equal number of patients were recruited
from primary and secondary care (Table 1).
The mean score of the CARAT among all patients for T1 was
19.4, with a standard deviation of 6.8 (Table 2). There was no ﬂoor
effect as no patients scored the minimum score of 0 (worst
control) but there was a small ceiling effect with four patients
scoring the maximum score of 30 (best control).
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Minimal clinically important difference
Mean CARAT scores for each GRC category are listed in Table 3.
The MCID for total CARAT scores, derived from the GRQ category
‘minimal difference’, is 3.50. CARAT scores showed an s.e.m.
of 2.83.
Internal consistency
The Cronbach’s alpha for the total CARAT questionnaire was 0.82
on T1, with an alpha of 0.81 for domain allergic rhinitis and 0.77
for domain asthma. Cronbach’s alpha for the total CARAT
questionnaire was 0.86 on T2 and 0.83 on T3.
Construct validity
Correlation coefﬁcients of CARAT total and domain scores with
ACQ5 and VAS scores are shown in Table 4. All a priori expected
best correlations were met.
Longitudinal validity
Correlation coefﬁcients between delta scores for the CARAT and
delta scores for the ACQ5 and VAS scores are shown in Table 5.
A priori expected correlations were conﬁrmed.
Test–retest reliability
Test–retest reliability of the CARAT was conﬁrmed by an ICC of 0.81
(Po0.01) for T1–T2 (n=44) and 0.80 (Po0.01) for T2–T3 (n=31).
Discriminative properties
On T1, the group with ‘well and partly controlled’ asthma
according to the ACQ5 (n= 70) had a mean CARAT score of
21.43 (s.d. 5.85). The group with ‘uncontrolled’ asthma according
to the ACQ5 (n= 22) showed a mean CARAT score of 12.77
(s.d. 5.32). The difference in means between both groups was
signiﬁcant (Po0.001).
Pollen counts
Correlation coefﬁcients of delta CARAT and ACQ5 scores with
delta pollen counts are shown in Table 6. Correlations with pollen
counts were higher for the CARAT than for ACQ5.
DISCUSSION
Main ﬁndings
This is the ﬁrst study that determines the MCID of the CARAT and
indicates that this stands at 3.5 points based on GRC analysis. As
the CARAT score is a whole-point scale, this outcome suggests
that a change in score of 4 points or more from baseline indicates
the smallest change in control of asthma and allergic rhinitis as
measured by the CARAT that can be considered as clinically
signiﬁcant. The determination of MCID is important for interpret-
ing CARAT scores and, therefore, is a vital step for implementation
Table 1. Patient characteristics
Characteristics Primary care Secondary care
Patients, n 46 46
Age in years, mean (s.d.) 46.6 (12.7) 41.3 (14.2)
Sex, n (%)
Male 19 (41.3) 11 (23.4)
Female 27 (58.7) 35 (76.6)
Diagnosis, n (%)
Asthma 26 (56.5) 26 (55.3)
Rhinitis 31 (67.4) 46 (100.0)
Age of onset in years, mean (s.d.)
Asthma 37.0 (15.1) 19.8 (14.5)
Rhinitis 32.7 (11.1) 19.4 (10.5)
Respiratory co-morbiditya n (%) 4 (8.7) 11 (23.9)
Type of allergenb, n (%)
Not allergic 12 (26.1) 1 (2.2)
Pollen 18 (39.1) 39 (84.8)
Non-pollen allergen 8 (17.4) 5 (10.9)
Unknown 8 (17.4) 1 (2.2)
ACQ5 score, mean (s.d.) 1.1 (1.2) 0.9 (0.9)
Skin prick test, n (%) 1 (2.2) 15 (32.6)
Speciﬁc IgE, n (%) 2 (4.4) 30 (65.2)
Lung function, n (%) 41 (89.1) 33 (71.7)
% predicted FEV1, mean (s.d.) 102.3 (14.4) 98.7 (15.4)
Medication usec, n (%)
Antihistamines
Local 1 (2.2) 7 (15.2)
Systemic 7 (15.2) 21 (45.7)
Corticosteroids
Nasal 10 (21.7) 32 (69.6)
Pulmonal 19 (41.3) 18 (39.1)
Systemic 2 (4.3) 3 (6.5)
B-sympathicomimetics
Short-acting 12 (26.1) 29 (63.0)
Long-acting 13 (28.3) 10 (21.7)
Leukotrien antagonists 4 (8.7) 8 (17.4)
Immunotherapy 0 (0.0) 3 (6.5)
Decongestives 3 (6.5) 0 (0.0)
Abbreviations: ACQ, Asthma Control Questionnaire; FEV1, forced expira-
tory volume in 1 second.
aChronic obstructive pulmonary disease exclusively.
bBased on history. Data for skin prick tests and speciﬁc IgE could not be
described because of different outcome measures at each centre.
cMedication as taken by patients.
Table 2. Mean CARAT scores
CARAT scores Mean (s.d.) n
CARAT T1 19.36 (6.80) 92
CARAT T1 ♀ 18.63 (6.59) 63
CARAT T1 ♂ 20.93 (7.11) 29
CARAT T1 age percentiles
o33 17.87 (7.07) 23
34–43 17.38 (7.64) 23
44–53 19.38 (7.04) 23
454 22.24 (4.88) 23
CARAT T2 19.99 (7.13) 82
CARAT T3 21.67 (6.51) 72
Abbreviation: CARAT, Control of Allergic Rhinitis and Asthma Test.
Table 3. Minimal clinically important difference
Difference category GRC Difference CARAT score mean
(s.d.)
None (n= 44) − 1, 0, 1 3.00 (2.79)
Minimal (n= 16) − 3, − 2, 2, 3 3.50 (2.78)
Moderate (n= 15) − 5, − 4, 4, − 5 7.07 (4.08)
Large (n= 7) − 7, − 6, 6, 7 5.57 (6.40)
The MCID (minimal clinically important difference) is shown in bold.
Abbreviations: CARAT, Control of Allergic Rhinitis and Asthma Test; GRC,
Global Rating of Change (−7 through 7).
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in clinical practice.22 This is also the ﬁrst study to investigate the
psychometric properties of the CARAT in another country than the
country of origin (Portugal) and we have found that the Dutch
CARAT is a valid tool with good internal consistency and
discriminative properties.
Strengths and limitations of this study
One of the strengths of this study is the determination of the
MCID by using both an anchor-based method and a distribution-
based method. In addition, both patients from primary and
secondary care were included in this study. This is also the ﬁrst
study reporting on the psychometric properties of the CARAT in
another country than the country of origin showing that it is valid
and reliable. Further, this was the ﬁrst study in which CARAT was
administered by mail. A limitation of this study is the attrition rate
at T2 and T3. For each measuring moment, the number of patients
reduces by 10. For this reason, the main focus in the interpretation
of the results lies with T1. The sample size for each measurement
(T1, T2 and T3) is considered sufﬁcient, as a number of 50–100
patients is usually what is needed in questionnaire validation
studies.28
Another limitation is that pollen counts were measured in
Leiden, whereas participants were recruited from Rotterdam,
Nijmegen, Groningen and Friesland. Although the maximum
distance between the pollen station and the centres is only
200 km, local ﬂuctuations of pollen counts may have occurred.
A ﬁnal limitation of the study is the incomplete descriptive
baseline characteristics concerning lung function, speciﬁc IgE and
skin prick tests, especially for primary care patients. However,
these are not standard clinical investigations in primary care and
all available data were included.
Interpretation of ﬁndings in relation to previously published work
The MCID of the CARAT was evaluated using both an anchor-
based method (GRC) and a distribution-based method (s.e.m.). The
rationale for using the s.e.m. as a tool to further conﬁrm the MCID
is that when a change is smaller than the s.e.m., it is probably a
measurement error rather than a true change.29 However, this
does not indicate whether the magnitude of change is important
for patients as perceived by patients.30 Therefore, from the clinical
point of view, the anchor-based method using GRC would be
preferred to establish MCID with the s.e.m. as an establishment
threshold. The establishment of the MCID of the CARAT has been
proposed as an important step for meeting COSMIN
requirements.28 With the CARAT meeting 9 out of 10 criteria so
far, this has been marked as a highly prioritised goal.22
The Dutch CARAT (total and domains) showed satisfactory
internal consistency, which was comparable to that of the
Portuguese CARAT study.20 With regard to the construct validity,
all a priori expectations were met. As expected, the CARAT asthma
domain showed good correlation with ACQ5, which measures
asthma control, and the CARAT allergic rhinitis domain showed
good correlation with VAS-up, which covers upper airway
symptoms. Comparisons of the CARAT domains with the lower
and upper airway domains vice versa showed lower correlation
coefﬁcients throughout. Thus, the separate CARAT domains
measure the supposed construct. These results were similar to
ﬁndings for the Portuguese version of the CARAT,20 underlining
good cross-sectional validity of the CARAT.
The Dutch CARAT showed satisfactory longitudinal validity as
well. Correlation coefﬁcients between delta scores of the CARAT
and delta scores of the ACQ5 and VAS questions were reasonably
high. These results underline ﬁndings in the Portuguese CARAT
study, which showed similar longitudinal results. The same was
true for the test–retest reliability of the Dutch CARAT.21 The Dutch
CARAT is also shown to be able to distinguish patients on the basis
of ACQ5 cut-off scores. Therefore, discriminative properties of the
Dutch CARAT are good when it comes to distinguishing ‘well
Table 4. Spearman correlations construct validity
T1 ACQ VAS-all VAS-low VAS-up VAS-low+up
CARAT total score − 0.66 −0.69 − 0.62 − 0.64 −0.76
CARAT domain allergic rhinitis − 0.41 − 0.47 − 0.41 −0.70 − 0.66
CARAT domain asthma −0.70 − 0.68 −0.64 − 0.44 − 0.71
Abbreviations: ACQ, Asthma Control Questionnaire; CARAT, Control of Allergic Rhinitis and Asthma Test; VAS-all, Visual Analog Scale-all airway symptoms;
VAS-low, Visual Analog Scale-lower airway symptoms; VAS-up, Visual Analog Scale-upper airway symptoms; VAS-low+up, Sum of VAS-low and VAS-up score.
All correlations were statistically signiﬁcant (Po0.01). The a priori expected best correlations are shown in bold.
Table 5. Spearman correlations longitudinal validity
Period 1 (T1-T2) Period 2 (T2-T3)
CARAT total scores
CARAT—ACQ 0.45 0.40
CARAT—VAS-all 0.61 0.45
CARAT—VAS-low+up 0.67 0.40
CARAT domains
Domain allergic rhinitis—VAS-up 0.55 0.36
Domain asthma—VAS-low 0.45 0.29
Domain asthma—ACQ 0.41 0.41
All correlations were statistically signiﬁcant (Po0.01). Period 1 represents
the 4-week period between T1 and T2, period 2 represents the 4-week
period between T2 and T3.
Abbreviations: ACQ, Asthma Control Questionnaire; CARAT, Control of
Allergic Rhinitis and Asthma Test; VAS-all, Visual Analog Scale-all airway
symptoms; VAS-low, Visual Analog Scale-lower airway symptoms; VAS-up,
Visual Analog Scale-upper airway symptoms; VAS-low+up, Sum of VAS-low
and VAS-up score.
Table 6. Longitudinal association of delta CARAT and ACQ scores with
delta pollen counts in patients with a history of clinical reactivity to
pollen
Delta pollen counts birch/grass
Period 1 (n= 49) Period 2 (n= 41)
Delta CARAT score 0.32 0.11
Delta ACQ score 0.10 0.06
All Pearson correlations were signiﬁcant (Po0.05). Period 1 represents the
4-week period between T1 and T2, period 2 represents the 4-week period
between T2 and T3.
Abbreviations: ACQ, Asthma Control Questionnaire; CARAT, Control of
Allergic Rhinitis and Asthma Test.
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controlled and partly controlled’ patients from ‘uncontrolled’
patients on the basis of ACQ5 scores.23
As expected, higher correlation coefﬁcients with pollen counts
were found for CARAT than for ACQ5. Although the correlation
coefﬁcients were not persuasively high, they suggest an associa-
tion between delta pollen counts and delta CARAT score.
Moreover, high correlations were not expected, given the fact
that the majority of patients in this study were well controlled and,
therefore, less likely to be sensitive to rising pollen counts.
Furthermore, patients suffering from allergic rhinitis have been
shown to have more severe symptoms in the early ﬂowering
season in relation to peaks in pollen counts, when compared with
peaks later in the same season.31 This can be explained by the fact
that patients allergic to pollen may have a potential to down-
regulate their allergic response after repeated allergen exposure.32
This could also explain the lower correlation coefﬁcients that were
found in the second interval (T2–T3).
Implications for further research, policy and practice
Validated questionnaires have been suggested as key instruments
for the evaluation of all airway symptoms.16–18 The Dutch CARAT is
therefore a valuable addition to existing questionnaires that
generally evaluate only lower airway symptoms.8–11 Accordingly,
the CARAT is a useful tool in the Netherlands for facilitating
optimal control of both asthma and allergic rhinitis simulta-
neously. This has been extensively proposed as a future goal to be
achieved.1,12
Conclusions
This is the ﬁrst study evaluating the MCID of the CARAT,
suggesting an MCID at 4 points. The determination of MCID is
highly important to be able to interpret CARAT scores and is a vital
step for implementation in clinical practice. The CARAT is a valid
and reliable tool for monitoring asthma and allergic rhinitis
symptoms simultaneously, which has been extensively proposed
by ARIA guidelines. Moreover, CARAT scores seem to be more
sensitive to changes in pollen counts when compared with ACQ5
scores.
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